Trevi Therapeutics (TRVI) Earnings Date & Reports

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

TRVI is expected to report earnings to rise 21.64% to -13 cents per share on May 08

Trevi Therapeutics TRVI Stock Earnings Reports

Q1'25

Est.

$-0.13

Q4'24

Beat

by $0.01

Q3'24

Missed

by $0.01

Q2'24

Missed

by $0.01

Q1'24

Missed

by $0.02

The last earnings report on March 18 showed earnings per share of -10 cents, beating the estimate of -11 cents. With 1.06M shares outstanding, the current market capitalization sits at 600.88M.

View a ticker or compare two or three

Compare

TRVI